Key statistics
On Friday, Basilea Pharmaceutica AG Allschwil (0QNA:LSE) closed at 56.61, -4.94% below its 52-week high of 59.55, set on Jul 29, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 56.61 |
| Low | 56.61 |
| Bid | -- |
| Offer | -- |
| Previous close | 57.60 |
| Average volume | 20.26k |
|---|---|
| Shares outstanding | 13.32m |
| Free float | 13.29m |
| P/E (TTM) | 11.00 |
| Market cap | 767.25m CHF |
| EPS (TTM) | 5.23 CHF |
Data delayed at least 20 minutes, as of Feb 06 2026 17:39 GMT.
More ▼
Announcements
- Basilea geht Partnerschaft mit INCATE ein, um Innovationen im Bereich Antipilzmittel zu unterstützen
- Basilea joins INCATE to support antifungal innovation
- Basilea informiert über Stand seines Portfolios und gibt Ausblick
- Basilea provides portfolio update and outlook
- Basilea and Prokaryotics enter collaboration to develop a novel broad-spectrum antifungal for the treatment of severe invasive infections
- Basilea und Prokaryotics starten Zusammenarbeit zur Entwicklung eines neuartigen Breitband-Antipilzmittels für die Behandlung schwerer invasiver Infektionen
- Basilea und Phare Bio gehen Partnerschaft zur Entwicklung eines neuartigen Antibiotikums ein - Kombination von industrieller Expertise und einzigartigen KI-Fähigkeiten
- Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic
- Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea
- Starke Verkaufszahlen für Cresemba® (Isavuconazol) in Europa lösen USD 30 Mio. Meilensteinzahlung an Basilea aus
More ▼
